Eligible Patient Profile for Leqembi Infusion
Leqembi infusion is intended for individuals diagnosed with mild cognitive impairment (MCI) due to Alzheimer's disease or mild dementia associated with Alzheimer's disease.
Patients must have confirmed brain amyloid pathology. This can be demonstrated through diagnostic tests such as an amyloid PET scan or cerebrospinal fluid (CSF) tests that indicate the presence of amyloid plaques, which are characteristic of Alzheimer's disease.
For those with MCI, there should be cognitive concerns reported by the patient, a knowledgeable informant, or a physician, along with objective impairment in one or more cognitive domains (e.g., memory, executive function) while still being able to perform most daily activities independently.
Leqembi infusion has not been tested in patients with more advanced stages of Alzheimer's disease or those without clinical symptoms. Therefore, it is not recommended for individuals who are in moderate to severe stages of dementia.
Our team is always here to help. Send us a message and we'll get back to you shortly.